Expert Insights

Ajay Nooka, MD, discusses practice-changing advances in multiple myeloma emerging from 2025 data.

John Leonard, MD, explores recent advances in mantle cell lymphoma.

Valentín Ortiz-Maldonado, MD, discusses results from the phase 2 CART19-BE-02 trial which assessed varnimcabtagene autoleucel in adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Cathy Eng, MD, discusses recent updates in anal carcinoma, highlighting rising incidence and ongoing unmet needs in advanced disease.

Danny Nguyen, MD, discusses the recent FDA approval of a new, simplified once-monthly dose of subcutaneous amivantamab for the first-line treatment of patients with EGFR-mutated advanced NSCLC.

Jonathan Anker, MD, PhD, discusses results from the phase 2 HCRN GU 2444 study evaluating a response-adapted bladder preservation strategy among cisplatin-ineligible patients with muscle-invasive bladder cancer.

Sarah Rutherford, MD, discusses recent advances in frontline treatment of diffuse large B-cell lymphoma and how emerging data are reshaping clinical practice.

Lindsay Rein, MD, discusses emerging therapeutic strategies across myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis.

Asher Chanan-Khan, MD, discusses recent advances in Waldenström’s macroglobulinemia including developments in BTK inhibitors, BCL2 combinations, and novel targeted therapies.

Mateo Mejia Saldarriaga, MD, discusses the unmet need in high-risk multiple myeloma, including extramedullary disease, CNS involvement, and plasma cell leukemia.